Hasmet Hanagasi

Hasmet Hanagasi

Auto-generated profile, based on publicly available information

Hasmet Hanagasi

Behavioural Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2020 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
GGGamze Guven
Gamze Guven
BBBasar Bilgic
Basar Bilgic
BSBedia Samanci
Bedia Samanci
HGHakan Gürvit
Hakan Gürvit
HHHasmet Hanagasi
Hasmet Hanagasi
NENihan Erginel-Unaltuna
Nihan Erginel-Unaltuna

25 January 2019 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
GGGamze Guven
Gamze Guven
EVEren Vurgun
Eren Vurgun
BBBasar Bilgic
Basar Bilgic
HHHasmet Hanagasi
Hasmet Hanagasi
HGHakan Gürvit
Hakan Gürvit
NENihan Erginel-Unaltuna
Nihan Erginel-Unaltuna

1 August 2021 in European Journal of Geriatrics and Gerontology
Verified
Journal Article
Closed access
Gülistan BahatGülistan Bahat
Gülistan Bahat
BIBirkan İlHan
Birkan İlHan
TETuğba Erdoğan
Tuğba Erdoğan
MHMeltem Halil
Meltem Halil
SSSumru Savas
Sumru Savas
MKMehmet AKİF Karan
Mehmet AKİF Karan

15 April 2021 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
GGGamze Guven
Gamze Guven
BSBedia Samanci
Bedia Samanci
CGCagri Gulec
Cagri Gulec
HHHasmet Hanagasi
Hasmet Hanagasi
HGHakan Gürvit
Hakan Gürvit
BBBasar Bilgic
Basar Bilgic

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
ÇUÇağrı Ulukan
Çağrı Ulukan
BSBedia Samancı
Bedia Samancı
EEEbru Erzurumluoğlu
Ebru Erzurumluoğlu
HHHasmet Hanagasi
Hasmet Hanagasi
GDGünnur Deniz
Günnur Deniz
EAEsi̇n Aktas-Cetin
Esi̇n Aktas-Cetin
Background: Nasu‐Hakola disease (NHD) is a rare genetic neurodegenerative disorder characterised by progressive presenile dementia and bone cysts. Dysfunctions in myeloid‐derived innate immune cells such as microglia due to loss‐of‐function mutations in the TREM2 (trigger receptor 2 expressed on myeloid cells) gene cause the clinical manifestations. Heterozygous carriers have strongly increased risk of developing Alzheimer’s Disease but do not present with NHD symptoms. TREM2 is associated with DAP12 protein, which contains an immunoreceptor tyrosine‐based activation motif that is structurally similar to natural killer (NK) cell receptors. In this study, we aimed to analyse the effects of TREM2 mutation and its effect on the peripheral immune system represented by NK cell functions.Method: Six patients with NHD with a defined homozygous TREM2 mutation, 7 carriers with heterozygous TREM2 mutations and 10 age‐ and gender‐matched controls were included. NK cell subsets, KIR expressions (NKG2A, NKG2D, NKp46), cytotoxic activity (CD107a, Perforin, Granzyme A) and cytokine secretions (IL‐4, IFN‐γ, TNF‐α, IL‐10, IL‐17, TGF‐β) were analysed by flow cytometry.Result: CD3−CD56dimCD16− (p = 0.003) subsets were found to be increased in the NHD group compared to carriers. Activating C‐type lectin receptor NKG2D expression was increased in CD8+ (p = 0.003) NK cell subsets in the NHD group. Inhibiting C‐type lectin receptor NKG2A expression was increased in total (p = 0.011) as well as CD8+ (p = 0.007) NK cell subsets in carriers compared to controls. In total NK cells, intracellular TNF‐α (p = 0.005) and TGF‐β (p = 0.013) levels were decreased, IL‐17 (p = 0.05) and IL‐4 (p = 0.005) levels were increased in the NHD group. When NK cells were grouped due to their CD8 expression, TNF‐α levels were decreased, and IL‐17 levels were increased in both subsets in the NHD group. Cytotoxic activity showed no differentiation in both unstimulated and K562 stimulated conditions between groups.Conclusion: Unlike previous case series, NK cell ratios did not differ between groups. Over‐expression of inhibiting receptors in the carriers group, unlike high levels of activating receptors in the NHD, might explain the lack of symptoms in the carriers. The increased ratio of CD3−CD56dimCD16− NK cell subsets that overexpress inhibitory checkpoints might explain the low levels of pro‐inflammatory cytokines in the NHD group.